A special supplement dedicated to the AI-Mind project has been published today alongside the 48th edition of Dementia in Europe Magazine, offering an in-depth look at the project’s progress, vision and ethical considerations in using Artificial Intelligence (AI) to support dementia risk prediction.

The supplement begins with the general description of the project followed by an overview of the AI-Mind study, a key part of the project enrolling 1,000 participants with mild cognitive impairment (MCI) aged 60-80 across five clinical centres. The collected data will help develop and validate the AI-Mind tools that predict who is at risk of developing dementia. The AI-Mind tools, namely the AI-Mind Connector and the AI-Mind Predictor, will be integrated into a cloud-based
diagnostic platform. Details of the collected data and how the AI-Mind tools are designed are also covered in the supplement.

The special supplement also highlights the essential role of public and patient involvement in shaping the ethical framework of AI in dementia care. Jean Georges, Executive Director of Alzheimer Europe, emphasised the importance of this in his foreword:

“Artificial Intelligence (AI) in this field is still relatively new, but rapidly evolving. This research can greatly benefit from the involvement of the general public, people with an interest in the topic and those experiencing cognitive problems. I am very proud of how Alzheimer Europe was able to include its views through its work on the ethical reflection on the use of AI-based dementia risk prediction in the clinical setting.”

We invite everyone with an interest in AI, neuroscience and dementia research to read the supplement and learn more about how AI-Mind is helping to shape the future of brain health in Europe.

Read the special supplement: https://bit.ly/AI-Mind_Supplement

Launched in March 2021, AI-Mind is a five-year initiative that has grown to include 17 partners across eight European countries. It unites a diverse network of experts from academic institutions, medical centres, SMEs, spin-offs, and patient organisations, all working towards a shared goal: improving future dementia diagnosis and care through innovation and collaboration.